{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:40Z","timestamp":1792788580301,"version":"4.5.0"},"reference-count":178,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Beijing Kangmeng Charity Foundation Health Development Promotion Project-Spark Program-Solid Tumor Research Project","award":["wsjk-XH20250516"],"award-info":[{"award-number":["wsjk-XH20250516"]}]},{"name":"the Research Special Project of the Sichuan Provincial Administration of Traditional Chinese Medicine","award":["25MSZX507"],"award-info":[{"award-number":["25MSZX507"]}],"id":[{"id":"https:\/\/ror.org\/03x55t826","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1245\/s10434-026-20016-5","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T13:53:15Z","timestamp":1784814795000},"page":"9539-9557","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early Identification and Management of Biochemical Recurrence Following Radical Prostatectomy"],"prefix":"10.1245","volume":"33","author":[{"given":"Yuxin","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fawei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shukui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"20016_CR1","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75:10\u201345.","journal-title":"CA Cancer J Clin."},{"key":"20016_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin."},{"key":"20016_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102630","volume":"122","author":"JA Efstathiou","year":"2024","unstructured":"Efstathiou JA, Morgans AK, Bland CS, Shore ND. Novel hormone therapy and coordination of care in high-risk biochemically recurrent prostate cancer. Cancer Treatment Rev. 2024;122:102630.","journal-title":"Cancer Treatment Rev."},{"key":"20016_CR4","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1002\/cam4.4092","volume":"10","author":"Q Su","year":"2021","unstructured":"Su Q, Liu Z, Chen C, Gao H, Zhu Y, Wang L, et al. Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy. Cancer Med. 2021;10:6492\u2013502.","journal-title":"Cancer Med."},{"key":"20016_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I, et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol. 2020;77:403\u201317.","journal-title":"Eur Urol."},{"key":"20016_CR6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1200\/EDBK_200319","volume":"38","author":"DE Spratt","year":"2018","unstructured":"Spratt DE, McHugh DJ, Morris MJ, Morgans AK. Management of biochemically recurrent prostate cancer:ensuring the right treatment of the right patient at the right time. Am Soc Clin Oncol Educ Book. 2018;38:355\u201362.","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"20016_CR7","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1097\/JU.0000000000003892","volume":"211","author":"TM Morgan","year":"2024","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, et al. Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline Part I\u2014introduction and treatment decision-making at the time of suspected biochemical recurrence after radical prostatectomy. J Urol. 2024;211:509\u201317.","journal-title":"J Urol."},{"key":"20016_CR8","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO guideline. J Urol. 2023;209:1082\u201390.","journal-title":"J Urol."},{"key":"20016_CR9","unstructured":"Spratt DE, Srinivas S, Adra N, Ahmed B, An Y, Bitting R, et al. NCCN guidelines index table of contents discussion. Prostate Cancer. 2025."},{"key":"20016_CR10","doi-asserted-by":"publisher","first-page":"e3618","DOI":"10.1016\/S1569-9056(19)34738-4","volume":"18","author":"C Parker","year":"2019","unstructured":"Parker C, Clarke NW, Cook A, Kynaston H, Petersen PM, Cross W, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): First results from RADICALS RT randomised controlled trial [NCT00541047]. Eur Urol Suppl. 2019;18:e3618\u20139.","journal-title":"Eur Urol Suppl."},{"key":"20016_CR11","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.annonc.2024.03.010","volume":"35","author":"CC Parker","year":"2024","unstructured":"Parker CC, Petersen PM, Cook AD, Clarke NW, Catton C, Cross WR, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047). Ann Oncol. 2024;35:656\u201366.","journal-title":"Ann Oncol."},{"key":"20016_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.clon.2022.06.004","volume":"34","author":"CC Parker","year":"2022","unstructured":"Parker CC, Clarke NW, Catton C, Kynaston H, Cook A, Cross W, et al. RADICALS-HD: reflections before the results are known. Clin Oncol. 2022;34:593\u20137.","journal-title":"Clin Oncol."},{"key":"20016_CR13","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","volume":"396","author":"CC Parker","year":"2020","unstructured":"Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;396:1413\u201321.","journal-title":"Lancet."},{"key":"20016_CR14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.52971","volume":"8","author":"A Holzgreve","year":"2025","unstructured":"Holzgreve A, Armstrong WR, Clark KJ, Benz MR, Smith CP, Djaileb L, et al. PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging. JAMA Netw Open. 2025;8:e2452971.","journal-title":"JAMA Netw Open."},{"key":"20016_CR15","unstructured":"LBA02-09 EMBARK: a phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer."},{"key":"20016_CR16","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","volume":"21","author":"P Sargos","year":"2020","unstructured":"Sargos P, Chabaud S, Latorzeff I, Magn\u00e9 N, Benyoucef A, Supiot S, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21:1341\u201352.","journal-title":"Lancet Oncol."},{"key":"20016_CR17","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","volume":"21","author":"A Kneebone","year":"2020","unstructured":"Kneebone A, Fraser-Browne C, Duchesne GM, Fisher R, Frydenberg M, Herschtal A, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.3\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020;21:1331\u201340.","journal-title":"Lancet Oncol."},{"key":"20016_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.32900","volume":"6","author":"UG Falagario","year":"2023","unstructured":"Falagario UG, Abbadi A, Remmers S, Bj\u00f6rnebo L, Bogdanovic D, Martini A, et al. Biochemical recurrence and risk of mortality following radiotherapy or radical prostatectomy. JAMA Netw Open. 2023;6:e2332900.","journal-title":"JAMA Netw Open."},{"key":"20016_CR19","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","volume":"75","author":"T Van den Broeck","year":"2019","unstructured":"Van den Broeck T, van den Bergh RCN, Arfi N, Gross T, Moris L, Briers E, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review. Eur Urol. 2019;75:967\u201387.","journal-title":"Eur Urol."},{"key":"20016_CR20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e17112","volume":"41","author":"N Khan","year":"2023","unstructured":"Khan N, McKay RR, Spratt DE, Constantinovici N, Chen G, Ortiz JA, et al. Biochemical recurrence (BCR) and outcomes in patients (pts) with prostate cancer (PC) following radical prostatectomy (RP). J Clin Oncol. 2023;41:e17112.","journal-title":"J Clin Oncol."},{"key":"20016_CR21","doi-asserted-by":"crossref","unstructured":"Health Commission of the PRC N, National Health Commission of the People\u2019s Republic of China. National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version). Chinese J Cancer Res. 2022;34:270\u201388.","DOI":"10.21147\/j.issn.1000-9604.2022.03.07"},{"key":"20016_CR22","first-page":"1","volume":"2014","author":"F Barchetti","year":"2014","unstructured":"Barchetti F, Panebianco V. Multiparametric MRI for recurrent prostate cancer post radical prostatectomy and postradiation therapy. BioMed Res Int. 2014;2014:1\u201323.","journal-title":"BioMed Res Int."},{"key":"20016_CR23","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1053\/j.semnuclmed.2004.06.004","volume":"34","author":"H Sch\u00f6der","year":"2004","unstructured":"Sch\u00f6der H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Sem Nucl Med. 2004;34:274\u201392.","journal-title":"Sem Nucl Med."},{"key":"20016_CR24","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/CU9.0000000000000242","volume":"18","author":"X Zhang","year":"2024","unstructured":"Zhang X, Ma Z. Head-to-head comparison of PSMA PET\/CT and mpMRI for detecting biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Curr Urol. 2024;18:177\u201384.","journal-title":"Curr Urol"},{"key":"20016_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5306\/wjco.v12.i2.61","volume":"12","author":"C Manfredi","year":"2021","unstructured":"Manfredi C, Fern\u00e1ndez-Pascual E, Linares-Espin\u00f3s E, Cou\u00f1ago F, Mart\u00ednez-Salamanca JI. New frontiers in focal therapy for prostate cancer: prostate-specific membrane antigen positron emission tomography\/magnetic resonance imaging. WJCO. 2021;12:61\u20138.","journal-title":"WJCO"},{"key":"20016_CR26","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2967\/jnumed.118.225276","volume":"61","author":"B Kranzb\u00fchler","year":"2020","unstructured":"Kranzb\u00fchler B, M\u00fcller J, Becker AS, Garcia Sch\u00fcler HI, Muehlematter U, Fankhauser CD, et al. Detection rate and localization of prostate cancer recurrence using 68Ga-PSMA-11 PET\/MRI in patients with low PSA values \u2264 0.5 ng\/mL. J Nucl Med. 2020;61:194\u2013201.","journal-title":"J Nucl Med."},{"key":"20016_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/MOU.0000000000000982","volume":"32","author":"R Mei","year":"2022","unstructured":"Mei R, Farolfi A, Morigi JJ, Fanti S. The role of prostate-specific membrane antigen PET\/computed tomography in the management of prostate cancer patients: Could we ask for more? Curr Opin Urol. 2022;32:269\u201376.","journal-title":"Curr Opin Urol."},{"key":"20016_CR28","doi-asserted-by":"publisher","first-page":"6134","DOI":"10.3390\/cancers14246134","volume":"14","author":"S Ong","year":"2022","unstructured":"Ong S, Pascoe C, Kelly BD, Ballok Z, Webb D, Bolton D, et al. Distant nodes seen on PSMA PET-CT staging predicts post-treatment progression in men with newly diagnosed prostate cancer: a prospective cohort study. Cancers. 2022;14:6134.","journal-title":"Cancers."},{"key":"20016_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1055\/s-0045-1804894","volume":"24","author":"PWP Mohan","year":"2025","unstructured":"Mohan PWP, Mahajan H, Kumar D, Aringhieri G, Cioni D. Detection accuracy of [68Ga] PSMA PET\/CT with rising PSA in prostate cancer. World J Nucl Med. 2025;24:144\u201354.","journal-title":"World J Nucl Med."},{"key":"20016_CR30","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/cancers15051376","volume":"15","author":"C Burgard","year":"2023","unstructured":"Burgard C, Hoffmann MA, Frei M, Buchholz H-G, Khreish F, Marlowe RJ, et al. Detection efficacy of 68Ga-PSMA-11 PET\/CT in biochemical recurrence of prostate cancer with very low pSA levels: a 7-year, two-center \u201creal-world\u201d experience. Cancers. 2023;15:1376.","journal-title":"Cancers."},{"key":"20016_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.14748\/ssm.v0i0.7692","volume":"54","author":"M Dyankova","year":"2022","unstructured":"Dyankova M, Dancheva Z, Dokova K, Klisarova A. Evaluation of hybrid PET\/CT imaging with the 68Ga-labelled PSMA ligand in patients with prostate cancer and biochemical progression in the low-range values of PSA after radical prostatectomy. SSM. 2022;54:29.","journal-title":"SSM."},{"key":"20016_CR32","doi-asserted-by":"publisher","first-page":"947","DOI":"10.2967\/jnumed.116.185538","volume":"58","author":"F Dietlein","year":"2017","unstructured":"Dietlein F, Kobe C, Neubauer S, Schmidt M, Stockter S, Fischer T, et al. PSA-stratified Performance of 18F- and 68Ga-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2017;58:947\u201352.","journal-title":"J Nucl Med."},{"key":"20016_CR33","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/diagnostics10060352","volume":"10","author":"C Madsen","year":"2020","unstructured":"Madsen C, \u00d8stergren P, Haarmark C. The value of 68Ga-PSMA PET\/CT following equivocal 18F-NaF PET\/CT in prostate cancer patients. Diagnostics. 2020;10:352.","journal-title":"Diagnostics."},{"key":"20016_CR34","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrurol.2016.26","volume":"13","author":"T Maurer","year":"2016","unstructured":"Maurer T, Eiber M, Schwaiger M, Gschwend JE. Current use of PSMA\u2013PET in prostate cancer management. Nat Rev Urol. 2016;13:226\u201335.","journal-title":"Nat Rev Urol."},{"key":"20016_CR35","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2967\/jnumed.117.196329","volume":"59","author":"FL Giesel","year":"2018","unstructured":"Giesel FL, Will L, Kesch C, Freitag M, Kremer C, Merkle J, et al. Biochemical recurrence of prostate cancer: initial results with [18F]PSMA-1007 PET\/CT. J Nucl Med. 2018;59:632\u20135.","journal-title":"J Nucl Med."},{"key":"20016_CR36","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ajur.2020.02.001","volume":"8","author":"Y Yuminaga","year":"2021","unstructured":"Yuminaga Y, Rothe C, Kam J, Beattie K, Arianayagam M, Bui C, et al. 68Ga-PSMA PET\/CT versus CT and bone scan for investigation of PSA failure post radical prostatectomy. Asian J Urol. 2021;8:170\u20135.","journal-title":"Asian J Urol."},{"key":"20016_CR37","doi-asserted-by":"publisher","first-page":"4185","DOI":"10.3390\/cancers15164185","volume":"15","author":"M Mojsak","year":"2023","unstructured":"Mojsak M, Szumowski P, Amelian A, Hladunski M, Kubas B, My\u015bliwiec J, et al. Application of 18F-PSMA-1007 PET\/MR imaging in early biochemical recurrence of prostate cancer: results of a prospective study of 60 patients with very low PSA levels \u2264 0.5 ng\/mL. Cancers. 2023;15:4185.","journal-title":"Cancers."},{"key":"20016_CR38","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","volume":"4","author":"FE Von Eyben","year":"2018","unstructured":"Von Eyben FE, Picchio M, Von Eyben R, Rhee H, Bauman G. 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus. 2018;4:686\u201393.","journal-title":"Eur Urol Focus."},{"key":"20016_CR39","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","volume":"70","author":"M Perera","year":"2016","unstructured":"Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive 68 ga\u2013prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70:926\u201337.","journal-title":"Eur Urol."},{"key":"20016_CR40","doi-asserted-by":"publisher","first-page":"157","DOI":"10.20892\/j.issn.2095-3941.2018.0288","volume":"16","author":"SHT Janice","year":"2019","unstructured":"Janice SHT, Charles XYG, Yen SK, Youquan L, Jeffrey KLT, Eu TC, et al. 68Gallium-labelled PSMA-PET\/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy. Cancer Biol Med. 2019;16:157.","journal-title":"Cancer Biol Med."},{"key":"20016_CR41","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00345-020-03490-8","volume":"39","author":"YJL Bodar","year":"2021","unstructured":"Bodar YJL, Jansen BHE, Van Der Voorn JP, Zwezerijnen GJC, Meijer D, Nieuwenhuijzen JA, et al. Detection of prostate cancer with 18F-DCFPyL PET\/CT compared to final histopathology of radical prostatectomy specimens: Is PSMA-targeted biopsy feasible? The DeTeCT Trial World J Urol. 2021;39:2439\u201346.","journal-title":"The DeTeCT Trial. World J Urol"},{"key":"20016_CR42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1097\/JU.0000000000001698","volume":"206","author":"KJ Pienta","year":"2021","unstructured":"Pienta KJ, Gorin MA, Rowe SP, Carroll PR, Pouliot F, Probst S, et al. A phase 2\/3 prospective multicenter study of the diagnostic accuracy of prostate specific membrane antigen PET\/CT with18F-DCFPyL in prostate cancer patients (OSPREY). J Urol. 2021;206:52\u201361.","journal-title":"J Urol."},{"key":"20016_CR43","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316.","journal-title":"Lancet."},{"key":"20016_CR44","doi-asserted-by":"publisher","first-page":"20500","DOI":"10.1038\/s41598-022-24688-3","volume":"12","author":"M Haidar","year":"2022","unstructured":"Haidar M, Abi-Ghanem AS, Moukaddam H, Jebai ME, Al Zakleet S, Al Rayess S, et al. 68Ga-PSMA PET\/CT in early relapsed prostate cancer patients after radical therapy. Sci Rep. 2022;12:20500.","journal-title":"Sci Rep."},{"key":"20016_CR45","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1097\/MNM.0000000000001770","volume":"44","author":"E Panagiotidis","year":"2023","unstructured":"Panagiotidis E, Fragkiadaki V, Papathanasiou N, Kypraios C, Liatsikos E, Klampatsas A, et al. Comparison of 18F-PSMA-1007 and 18F-choline PET\/CT in prostate cancer patients with biochemical recurrence:a phase 3, prospective, multicenter, randomized study. Nucl Med Comm. 2023;44:1126\u201334.","journal-title":"Nucl Med Comm."},{"key":"20016_CR46","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.semnuclmed.2023.02.006","volume":"53","author":"V Jeet","year":"2023","unstructured":"Jeet V, Parkinson B, Song R, Sharma R, Hoyle M. Histopathologically validated diagnostic accuracy of PSMA-PET\/CT in the primary and secondary staging of prostate cancer and the impact of PSMA-PET\/CT on clinical management: a systematic review and meta-analysis. Sem Nucl Med. 2023;53:706\u201318.","journal-title":"Sem Nucl Med."},{"key":"20016_CR47","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1148\/radiol.220218","volume":"305","author":"GA Ulaner","year":"2022","unstructured":"Ulaner GA, Thomsen B, Bassett J, Torrey R, Cox C, Lin K, et al. 18F-DCFPyL PET\/CT for initially diagnosed and biochemically recurrent prostate cancer: prospective trial with pathologic confirmation. Radiology. 2022;305:419\u201328.","journal-title":"Radiology."},{"key":"20016_CR48","doi-asserted-by":"publisher","first-page":"668","DOI":"10.2967\/jnumed.115.154153","volume":"56","author":"M Eiber","year":"2015","unstructured":"Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET\/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56:668\u201374.","journal-title":"J Nucl Med."},{"key":"20016_CR49","doi-asserted-by":"publisher","first-page":"240","DOI":"10.2967\/jnumed.120.261886","volume":"63","author":"JJ Cerci","year":"2022","unstructured":"Cerci JJ, Fanti S, Lobato EE, Kunikowska J, Alonso O, Medina S, et al. Diagnostic performance and clinical impact of 68Ga-PSMA-11 PET\/CT imaging in early relapsed prostate cancer after radical therapy: a prospective multicenter study (IAEA-PSMA study). J Nucl Med. 2022;63:240\u20137.","journal-title":"J Nucl Med."},{"key":"20016_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.684629","volume":"11","author":"R Wang","year":"2021","unstructured":"Wang R, Shen G, Huang M, Tian R. The diagnostic role of 18F-choline, 18F-fluciclovine and 18F-PSMA PET\/CT in the detection of prostate cancer with biochemical recurrence: a meta-analysis. Front Oncol. 2021;11:684629.","journal-title":"Front Oncol."},{"key":"20016_CR51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET\/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197\u2013209.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"20016_CR52","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1148\/radiol.2020191689","volume":"296","author":"N Tan","year":"2020","unstructured":"Tan N, Oyoyo U, Bavadian N, Ferguson N, Mukkamala A, Calais J, et al. PSMA-targeted radiotracers versus 18F fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. Radiology. 2020;296:44\u201355.","journal-title":"Radiology."},{"key":"20016_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.911146","volume":"12","author":"X Liu","year":"2022","unstructured":"Liu X, Jiang T, Gao C, Liu H, Sun Y, Zou Q, et al. Detection rate of fluorine-18 prostate-specific membrane antigen-1007 PET\/CT for prostate cancer in primary staging and biochemical recurrence with different serum PSA levels: a systematic review and meta-analysis. Front Oncol. 2022;12:911146.","journal-title":"Front Oncol."},{"key":"20016_CR54","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/diagnostics12010195","volume":"12","author":"MT Christensen","year":"2022","unstructured":"Christensen MT, Jochumsen MR, Klingenberg S, S\u00f8rensen KD, Borre M, Bouchelouche K. Evaluation of predictors of biochemical recurrence in prostate cancer patients, as detected by 68Ga-PSMA PET\/CT. Diagnostics. 2022;12:195.","journal-title":"Diagnostics."},{"key":"20016_CR55","doi-asserted-by":"publisher","first-page":"202","DOI":"10.2967\/jnumed.119.229542","volume":"61","author":"F Dietlein","year":"2020","unstructured":"Dietlein F, Hohberg M, Kobe C, Zlatopolskiy BD, Krapf P, Endepols H, et al. An 18F-labeled PSMA ligand for PET\/CT of prostate cancer: first-in-humans observational study and clinical experience with 18F-JK-PSMA-7 during the first year of application. J Nucl Med. 2020;61:202\u20139.","journal-title":"J Nucl Med."},{"key":"20016_CR56","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1002\/jmri.29386","volume":"61","author":"BS Abrahamsen","year":"2025","unstructured":"Abrahamsen BS, Tandstad T, Aksness\u00e6ther BY, Bogsrud TV, Castillejo M, Hernes E, et al. Added value of [18F] PSMA-1007 PET\/CT and PET\/MRI in patients with biochemically recurrent prostate cancer: impact on detection rates and clinical management. Magn Reson Imaging. 2025;61:466\u201377.","journal-title":"Magn Reson Imaging."},{"key":"20016_CR57","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00345-020-03344-3","volume":"39","author":"E Mena","year":"2021","unstructured":"Mena E, Black PC, Rais-Bahrami S, Gorin M, Allaf M, Choyke P. Novel PET imaging methods for prostate cancer. World J Urol. 2021;39:687\u201399.","journal-title":"World J Urol."},{"key":"20016_CR58","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.3390\/diagnostics11112068","volume":"11","author":"P Mapelli","year":"2021","unstructured":"Mapelli P, Ghezzo S, Samanes Gajate AM, Preza E, Brembilla G, Cucchiara V, et al. Preliminary results of an ongoing prospective clinical trial on the use of 68Ga-PSMA and 68Ga-DOTA-RM2 PET\/MRI in staging of high-risk prostate cancer patients. Diagnostics. 2021;11:2068.","journal-title":"Diagnostics."},{"key":"20016_CR59","doi-asserted-by":"publisher","first-page":"1169189","DOI":"10.3389\/fonc.2023.1169189","volume":"13","author":"A Zheng","year":"2023","unstructured":"Zheng A, Wang Z, Luo L, Chang R, Gao J, Wang B, et al. The prognostic value of 18F-PSMA-1007 PET\/CT in predicting pathological upgrading of newly diagnosed prostate cancer from systematic biopsy to radical prostatectomy. Front Oncol. 2023;13:1169189.","journal-title":"Front Oncol."},{"key":"20016_CR60","doi-asserted-by":"publisher","DOI":"10.1111\/bju.70115","author":"Y Khanna","year":"2026","unstructured":"Khanna Y, Chinni V, Gnanasambantham K, Paul E, O\u2019Sullivan R, Ballok ZE, et al. Does addition of multiparametric MRI to PSMA PET\/CT improve diagnostic accuracy for biochemical recurrence after radical prostatectomy? BJU Int. 2026. https:\/\/doi.org\/10.1111\/bju.70115.","journal-title":"BJU Int."},{"key":"20016_CR61","doi-asserted-by":"publisher","first-page":"591","DOI":"10.2217\/fon-2018-0546","volume":"15","author":"HT Borno","year":"2019","unstructured":"Borno HT, Small EJ. Apalutamide and its use in the treatment of prostate cancer. Future Oncol. 2019;15:591\u20139.","journal-title":"Future Oncol."},{"key":"20016_CR62","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1748-717X-8-170","volume":"8","author":"WC Jackson","year":"2013","unstructured":"Jackson WC, Johnson SB, Li D, Foster C, Foster B, Song Y, et al. A prostate-specific antigen doubling time of <\u00a06 months is prognostic for metastasis and prostate cancer-specific death for patients receiving salvage radiation therapy post radical prostatectomy. Radiat Oncol. 2013;8:170.","journal-title":"Radiat Oncol."},{"key":"20016_CR63","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, De Almeida Luz M, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389:1453\u201365.","journal-title":"N Engl J Med."},{"key":"20016_CR64","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1200\/jco.2013.31.6_suppl.167","volume":"31","author":"WC Jackson","year":"2013","unstructured":"Jackson WC, Johnson SB, Foster B, Foster C, Song Y, Li D, et al. PSA doubling time of \u2264\u00a06 months as the optimal cutoff for predicting clinically relevant outcomes for men receiving salvage radiation therapy post radical prostatectomy. J Clin Oncol. 2013;31:167\u201377.","journal-title":"J Clin Oncol."},{"key":"20016_CR65","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","volume":"281","author":"CR Pound","year":"1999","unstructured":"Pound CR. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591.","journal-title":"JAMA"},{"key":"20016_CR66","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2023.05.038","volume":"85","author":"F Preisser","year":"2024","unstructured":"Preisser F, Abrams-Pompe RS, Stelwagen PJ, B\u00f6hmer D, Zattoni F, Magli A, et al. European Association of Urology biochemical recurrence risk classification as a decision tool for salvage radiotherapy: a multicenter study. Eur Urol. 2024;85:164\u201370.","journal-title":"Eur Urol."},{"key":"20016_CR67","doi-asserted-by":"publisher","first-page":"15307","DOI":"10.1038\/s41598-024-65969-3","volume":"14","author":"S Sakamoto","year":"2024","unstructured":"Sakamoto S, Sato K, Kimura T, Matsui Y, Shiraishi Y, Hashimoto K, et al. PSA doubling time 4.65 months as an optimal cut-off of Japanese nonmetastatic castration-resistant prostate cancer. Sci Rep. 2024;14:15307.","journal-title":"Sci Rep."},{"key":"20016_CR68","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/JU.0000000000003891","volume":"211","author":"TM Morgan","year":"2024","unstructured":"Morgan TM, Boorjian SA, Buyyounouski MK, Chapin BF, Chen DYT, Cheng HH, et al. Salvage therapy for prostate cancer: AUA\/ASTRO\/SUO guideline part II: treatment delivery for non-metastatic biochemical recurrence after primary radical prostatectomy. J Urol. 2024;211:518\u201325.","journal-title":"J Urol."},{"key":"20016_CR69","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3390\/cancers17020215","volume":"17","author":"MU Karim","year":"2025","unstructured":"Karim MU, Tisseverasinghe S, Cartes R, Martinez C, Bahoric B, Niazi T. Early versus delayed androgen deprivation therapy for biochemical recurrence after local curative treatment in non-metastatic hormone-sensitive prostate cancer: a systematic review of the literature. Cancers. 2025;17:215.","journal-title":"Cancers."},{"key":"20016_CR70","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s40644-024-00752-1","volume":"24","author":"S Harsini","year":"2024","unstructured":"Harsini S, Martineau P, Plaha S, Saprunoff H, Chen C, Bishop J, et al. Prognostic significance of a negative PSMA PET\/CT in biochemical recurrence of prostate cancer. Cancer Imaging. 2024;24:117.","journal-title":"Cancer Imaging."},{"key":"20016_CR71","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3390\/diagnostics15101224","volume":"15","author":"S Rais-Bahrami","year":"2025","unstructured":"Rais-Bahrami S, Davis P, Chau A, Galgano SJ, Chapin BF, Schuster DM, et al. Detection rates of PSMA-PET radiopharmaceuticals in recurrent prostate cancer: a systematic review. Diagnostics. 2025;15:1224.","journal-title":"Diagnostics."},{"key":"20016_CR72","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.15419\/bmrat.v5i12.511","volume":"5","author":"MB Shah","year":"2018","unstructured":"Shah MB, Raju K, Kumar GH. Revisiting prostate biopsy with 2014 ISUP modified Gleason score and Gleason grade: a cross-section study. Biomed Res Ther. 2018;5:2918\u201325.","journal-title":"Biomed Res Ther."},{"key":"20016_CR73","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/bju.15556","volume":"128","author":"DMZB Hennes","year":"2021","unstructured":"Hennes DMZB, Sewell J, Kerger M, Hovens CM, Peters JS, Costello AJ, et al. The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade. BJU Int. 2021;128:45\u201351.","journal-title":"BJU Int."},{"key":"20016_CR74","doi-asserted-by":"publisher","first-page":"646","DOI":"10.3389\/fonc.2019.00646","volume":"9","author":"X Zhu","year":"2019","unstructured":"Zhu X, Gou X, Zhou M. Nomograms predict survival advantages of Gleason score 3\u00a0+\u00a04 over 4\u00a0+\u00a03 for prostate cancer: a SEER-based study. Front Oncol. 2019;9:646.","journal-title":"Front Oncol."},{"key":"20016_CR75","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10147-019-01561-4","volume":"25","author":"T Hashimoto","year":"2020","unstructured":"Hashimoto T, Nakashima J, Inoue R, Komori O, Yamaguchi Y, Kashima T, et al. The significance of micro-lymphatic invasion and pathological Gleason score in prostate cancer patients with pathologically organ-confined disease and negative surgical margins after robot-assisted radical prostatectomy. Int J Clin Oncol. 2020;25:377\u201383.","journal-title":"Int J Clin Oncol."},{"key":"20016_CR76","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1080\/21681805.2016.1263237","volume":"51","author":"F Aoun","year":"2017","unstructured":"Aoun F, Albisinni S, Henriet B, Tombal B, Van Velthoven R, Roumegu\u00e8re T. Predictive factors associated with biochemical recurrence following radical prostatectomy for pathological T2 prostate cancer with negative surgical margins. Scand J Urol. 2017;51:20\u20136.","journal-title":"Scand J Urol."},{"key":"20016_CR77","doi-asserted-by":"crossref","unstructured":"Tilki D, Van Den Bergh RCN, Briers E, Van Den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II\u20142024 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2024;86:164\u201382.","DOI":"10.1016\/j.eururo.2024.04.010"},{"key":"20016_CR78","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41379-020-0625-x","volume":"34","author":"E Hollemans","year":"2021","unstructured":"Hollemans E, Verhoef EI, Bangma CH, Rietbergen J, Osanto S, Pelger RCM, et al. Cribriform architecture in radical prostatectomies predicts oncological outcome in Gleason score 8 prostate cancer patients. Mod Pathol. 2021;34:184\u201393.","journal-title":"Mod Pathol."},{"issue":"3","key":"20016_CR79","doi-asserted-by":"publisher","first-page":"302","DOI":"10.5173\/ceju.2015.485","volume":"68","author":"A Aguilera","year":"2015","unstructured":"Aguilera A, Ba\u00f1uelos B, D\u00edez J, Alonso-Dorrego JM, Cisneros J, Pe\u00f1a J. Biochemical recurrence risk factors in surgically treated high and very high-risk prostate tumors. Cent Eur J Urol. 2015;68(3):302. https:\/\/doi.org\/10.5173\/ceju.2015.485.","journal-title":"Cent Eur J Urol."},{"key":"20016_CR80","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3892\/ol.2023.13870","volume":"26","author":"C-K Yang","year":"2023","unstructured":"Yang C-K, Yang C-R, Ou Y-C, Cheng C-L, Ho H-C, Chiu K-Y, et al. Prostate-specific antigen density and preoperative MRI findings as predictors of biochemical recurrence in high-risk and very high-risk prostate cancer. Oncol Lett. 2023;26:284.","journal-title":"Oncol Lett."},{"key":"20016_CR81","doi-asserted-by":"publisher","first-page":"5039","DOI":"10.1002\/cncr.26169","volume":"117","author":"MR Cooperberg","year":"2011","unstructured":"Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. 2011;117:5039\u201346.","journal-title":"Cancer."},{"key":"20016_CR82","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.eururo.2015.03.036","volume":"69","author":"M Moschini","year":"2016","unstructured":"Moschini M, Sharma V, Zattoni F, Quevedo JF, Davis BJ, Kwon E, et al. Natural history of clinical recurrence patterns of lymph node-positive prostate cancer after radical prostatectomy. Eur Urol. 2016;69:135\u201342.","journal-title":"Eur Urol."},{"key":"20016_CR83","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.7150\/jca.29714","volume":"10","author":"JK Kim","year":"2019","unstructured":"Kim JK, Jeong CW, Ku JH, Kim HH, Kwak C. Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients. J Cancer. 2019;10:2237\u201342.","journal-title":"J Cancer."},{"key":"20016_CR84","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.eururo.2017.09.027","volume":"73","author":"KA Touijer","year":"2018","unstructured":"Touijer KA, Karnes RJ, Passoni N, Sjoberg DD, Assel M, Fossati N, et al. Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: a comparative analysis of different postoperative management strategies. Eur Urol. 2018;73:890\u20136.","journal-title":"Eur Urol."},{"key":"20016_CR85","doi-asserted-by":"publisher","first-page":"32238","DOI":"10.18632\/oncotarget.22459","volume":"9","author":"H Liu","year":"2018","unstructured":"Liu H, Zhou H, Yan L, Ye T, Lu H, Sun X, et al. Prognostic significance of six clinicopathological features for biochemical recurrence after radical prostatectomy:a systematic review and meta-analysis. Oncotarget. 2018;9:32238\u201349.","journal-title":"Oncotarget."},{"key":"20016_CR86","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41391-020-00283-3","volume":"24","author":"L Lunger","year":"2021","unstructured":"Lunger L, Retz M, Bandur M, Souchay M, Vitzthum E, J\u00e4ger M, et al. KLK3 and TMPRSS2 for molecular lymph-node staging in prostate cancer patients undergoing radical prostatectomy. Prostate Cancer Prostatic Dis. 2021;24:362\u20139.","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"20016_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0256778","volume":"16","author":"D Kim","year":"2021","unstructured":"Kim D, Kim D-Y, Kim J-S, Hong SK, Byun S-S, Lee SE. Clinical outcomes of salvage treatment in lymph node-positive prostate cancer patients after radical prostatectomy. PLoS ONE. 2021;16:e0256778.","journal-title":"PLoS ONE."},{"key":"20016_CR88","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12894-023-01228-3","volume":"23","author":"P Doan","year":"2023","unstructured":"Doan P, Katelaris A, Scheltema MJ, Hayen A, Amin A, Siriwardana A, et al. The relationship between biochemical recurrence and number of lymph nodes removed during surgery for localized prostate cancer. BMC Urol. 2023;23:68.","journal-title":"BMC Urol."},{"key":"20016_CR89","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1097\/JS9.0000000000000997","volume":"110","author":"G Ding","year":"2024","unstructured":"Ding G, Tang G, Wang T, Zou Q, Cui Y, Wu J. A comparative analysis of perioperative complications and biochemical recurrence between standard and extended pelvic lymph node dissection in prostate cancer patients undergoing radical prostatectomy:a systematic review and meta-analysis. Int J Surg. 2024;110:1735\u201343.","journal-title":"Int J Surg."},{"key":"20016_CR90","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.eururo.2013.07.039","volume":"65","author":"O Yossepowitch","year":"2014","unstructured":"Yossepowitch O, Briganti A, Eastham JA, Epstein J, Graefen M, Montironi R, et al. Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. Eur Urol. 2014;65:303\u201313.","journal-title":"Eur Urol."},{"key":"20016_CR91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0301653","volume":"19","author":"H Guo","year":"2024","unstructured":"Guo H, Zhang L, Shao Y, An K, Hu C, Liang X, et al. The impact of positive surgical margin parameters and pathological stage on biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis. PLoS ONE. 2024;19:e0301653.","journal-title":"PLoS ONE."},{"key":"20016_CR92","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/s41391-023-00654-6","volume":"26","author":"A John","year":"2023","unstructured":"John A, Lim A, Catterwell R, Selth L, O\u2019Callaghan M. Length of positive surgical margins after radical prostatectomy: does size matter? A systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2023;26:673\u201380.","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"20016_CR93","doi-asserted-by":"publisher","DOI":"10.1111\/bju.70136","author":"J Van Drumpt","year":"2026","unstructured":"Van Drumpt J, Baas D, Aben K, Van Leenders A, Kiemeney L, Sedelaar M, et al. Impact of positive surgical margins on biochemical recurrence and metastases after radical prostatectomy. BJU Int. 2026. https:\/\/doi.org\/10.1111\/bju.70136.","journal-title":"BJU Int."},{"issue":"16","key":"20016_CR94","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1002\/pros.23908","volume":"79","author":"F Preisser","year":"2019","unstructured":"Preisser F, Coxilha G, Heinze A, Oh S, Chun FKH, Sauter G, et al. Impact of positive surgical margin length and Gleason grade at the margin on biochemical recurrence in patients with organ-confined prostate cancer. Prostate. 2019;79(16):1832\u20136.","journal-title":"Prostate."},{"key":"20016_CR95","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1158\/1055-9965.EPI-22-0906","volume":"32","author":"RL Kokts-Porietis","year":"2023","unstructured":"Kokts-Porietis RL, Morielli AR, McNeil J, Courneya KS, Cook LS, Friedenreich CM. Prospective cohort of pre- and post-diagnosis diet with survival outcomes: an Alberta Endometrial Cancer cohort study. Cancer Epidemiol Biomarkers Prev. 2023;32:242\u201351.","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"20016_CR96","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1756283X14538689","volume":"7","author":"E Long","year":"2014","unstructured":"Long E, Beales ILP. The role of obesity in oesophageal cancer development. Therap Adv Gastroenterol. 2014;7:247\u201368.","journal-title":"Therap Adv Gastroenterol."},{"key":"20016_CR97","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/jjco\/hyh078","volume":"34","author":"K Kiyoshima","year":"2004","unstructured":"Kiyoshima K. Anatomical features of periprostatic tissue and its surroundings:a histological analysis of 79 radical retropubic prostatectomy specimens. Japanese J Clin Oncol. 2004;34:463\u20138.","journal-title":"Japanese J Clin Oncol."},{"key":"20016_CR98","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/cncr.11231","volume":"97","author":"H Hong","year":"2003","unstructured":"Hong H, Koch MO, Foster RS, Bihrle R, Gardner TA, Fyffe J, et al. Anatomic distribution of periprostatic adipose tissue: a mapping study of 100 radical prostatectomy specimens. Cancer. 2003;97:1639\u201343.","journal-title":"Cancer."},{"key":"20016_CR99","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3390\/cancers12061385","volume":"12","author":"D Miladinovic","year":"2020","unstructured":"Miladinovic D, Cusick T, Mahon KL, Haynes A-M, Cortie CH, Meyer BJ, et al. Assessment of periprostatic and subcutaneous adipose tissue lipolysis and adipocyte size from men with localized prostate cancer. Cancers. 2020;12:1385.","journal-title":"Cancers."},{"key":"20016_CR100","doi-asserted-by":"publisher","first-page":"20896","DOI":"10.1038\/s41598-024-71862-w","volume":"14","author":"S Jiang","year":"2024","unstructured":"Jiang S, Li Y, Guo Y, Gong B, Wei C, Liu W, et al. MRI-measured periprostatic to subcutaneous adipose tissue thickness ratio as an independent risk factor in prostate cancer patients undergoing radical prostatectomy. Sci Rep. 2024;14:20896.","journal-title":"Sci Rep."},{"key":"20016_CR101","doi-asserted-by":"publisher","first-page":"10230","DOI":"10.1038\/ncomms10230","volume":"7","author":"V Laurent","year":"2016","unstructured":"Laurent V, Gu\u00e9rard A, Mazerolles C, Le Gonidec S, Toulet A, Nieto L, et al. Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity. Nat Commun. 2016;7:10230.","journal-title":"Nat Commun."},{"key":"20016_CR102","doi-asserted-by":"publisher","first-page":"W43","DOI":"10.2214\/AJR.14.12689","volume":"204","author":"S Woo","year":"2015","unstructured":"Woo S, Cho JY, Kim SY, Kim SH. Periprostatic fat thickness on MRI: correlation with Gleason score in prostate cancer. Am J Roentgenol. 2015;204:W43\u20137.","journal-title":"Am J Roentgenol."},{"key":"20016_CR103","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3892\/ol.2024.14617","volume":"28","author":"I-H Shao","year":"2024","unstructured":"Shao I-H, Chang T-H, Chang Y-H, Hsieh Y-H, Sheng T-W, Wang L-J, et al. Periprostatic adipose tissue inhibits tumor progression by secreting apoptotic factors: a natural barrier induced by the immune response during the early stages of prostate cancer. Oncol Lett. 2024;28:485.","journal-title":"Oncol Lett."},{"key":"20016_CR104","doi-asserted-by":"publisher","first-page":"2201964","DOI":"10.1080\/21623945.2023.2201964","volume":"12","author":"T Xiong","year":"2023","unstructured":"Xiong T, Cao F, Zhu G, Ye X, Cui Y, Xing N, et al. MRI-measured periprostatic adipose tissue volume as a prognostic predictor in prostate cancer patients undergoing laparoscopic radical prostatectomy. Adipocyte. 2023;12:2201964.","journal-title":"Adipocyte."},{"key":"20016_CR105","doi-asserted-by":"publisher","first-page":"8970","DOI":"10.3390\/ijms25168970","volume":"25","author":"A Suzuki","year":"2024","unstructured":"Suzuki A, Sato S, Nakaigawa N, Kishida T, Miyagi Y. Combination of blood adiponectin and leptin levels is a predictor of biochemical recurrence in prostate cancer invading the surrounding adipose tissue. Int J Mol Sci. 2024;25:8970.","journal-title":"Int J Mol Sci."},{"key":"20016_CR106","doi-asserted-by":"publisher","first-page":"161","DOI":"10.18521\/ktd.1472283","volume":"16","author":"\u00d6 Efilo\u011flu","year":"2024","unstructured":"Efilo\u011flu \u00d6, \u0130plik\u00e7i A, G\u00fcnd\u00fcz N, Dogan MB, \u00c7ak\u0131c\u0131 M\u00c7, Y\u0131ld\u0131r\u0131m A. Impact of subcutaneous fat thickness on biochemical recurrence and recurrence-free survival in patients undergoing radical prostatectomy. Konuralp T\u0131p Dergisi. 2024;16:161\u20137.","journal-title":"Konuralp T\u0131p Dergisi."},{"key":"20016_CR107","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1245\/s10434-023-14691-x","volume":"31","author":"M Kawase","year":"2024","unstructured":"Kawase M, Ebara S, Tatenuma T, Sasaki T, Ikehata Y, Nakayama A, et al. Prognostic importance of lymphovascular invasion for specific subgroup of patients with prostate cancer after robot-assisted radical prostatectomy (The MSUG94 Group). Ann Surg Oncol. 2024;31:2154\u201362.","journal-title":"Ann Surg Oncol."},{"key":"20016_CR108","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s00345-025-05749-4","volume":"43","author":"Y Ozawa","year":"2025","unstructured":"Ozawa Y, Sharma R, Moschovas MC, Saikali S, Gamal A, Sandri M, et al. Prognostic significance of perineural invasion and lymphovascular invasion following robot-assisted radical prostatectomy with negative surgical margins:a retrospective study from a high-volume center. World J Urol. 2025;43:536.","journal-title":"World J Urol."},{"key":"20016_CR109","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.3390\/cancers14143466","volume":"14","author":"S Yamashita","year":"2022","unstructured":"Yamashita S, Muraoka S, Wakamiya T, Kikkawa K, Kohjimoto Y, Hara I. Prognostic impact of lymphatic invasion in patients with high-risk prostate cancer after robot-assisted radical prostatectomy and extended lymph node dissection: a single-institution prospective cohort study. Cancers. 2022;14:3466.","journal-title":"Cancers."},{"key":"20016_CR110","doi-asserted-by":"publisher","first-page":"1226366","DOI":"10.3389\/fonc.2023.1226366","volume":"13","author":"DH Chung","year":"2023","unstructured":"Chung DH, Han JH, Jeong S-H, Yuk HD, Jeong CW, Ku JH, et al. Role of lymphatic invasion in predicting biochemical recurrence after radical prostatectomy. Front Oncol. 2023;13:1226366.","journal-title":"Front Oncol."},{"key":"20016_CR111","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.euros.2024.09.007","volume":"69","author":"J Karwacki","year":"2024","unstructured":"Karwacki J, Stodolak M, D\u0142ubak A, Nowak \u0141, Gurwin A, Kowalczyk K, et al. Association of lymphovascular invasion with biochemical recurrence and adverse pathological characteristics of prostate cancer: a systematic review and meta-analysis. Eur Urol Open Sci. 2024;69:112\u201326.","journal-title":"Eur Urol Open Sci."},{"key":"20016_CR112","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013537","volume":"97","author":"W Jiang","year":"2018","unstructured":"Jiang W, Zhang L, Wu B, Zha Z, Zhao H, Jun Y, et al. The impact of lymphovascular invasion in patients with prostate cancer following radical prostatectomy and its association with their clinicopathological features: an updated PRISMA-compliant systematic review and meta-analysis. Medicine. 2018;97:e13537.","journal-title":"Medicine."},{"key":"20016_CR113","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3390\/cancers16010123","volume":"16","author":"NJ Sathianathen","year":"2023","unstructured":"Sathianathen NJ, Furrer MA, Mulholland CJ, Katsios A, Soliman C, Lawrentschuk N, et al. Lymphovascular invasion at the time of radical prostatectomy adversely impacts oncological outcomes. Cancers. 2023;16:123.","journal-title":"Cancers."},{"key":"20016_CR114","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.adro.2018.09.006","volume":"4","author":"RD Kraus","year":"2019","unstructured":"Kraus RD, Barsky A, Ji L, Garcia Santos PM, Cheng N, Groshen S, et al. The perineural invasion paradox: is perineural invasion an independent prognostic indicator of biochemical recurrence risk in patients with pT2N0R0 prostate cancer? A multi-institutional study. Adv Radiat Oncol. 2019;4:96\u2013102.","journal-title":"Adv Radiat Oncol."},{"key":"20016_CR115","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.3390\/cancers14174065","volume":"14","author":"Y Niu","year":"2022","unstructured":"Niu Y, F\u00f6rster S, Muders M. The role of perineural invasion in prostate cancer and its prognostic significance. Cancers. 2022;14:4065.","journal-title":"Cancers."},{"key":"20016_CR116","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12894-018-0319-6","volume":"18","author":"L Zhang","year":"2018","unstructured":"Zhang L, Wu B, Zha Z, Qu W, Zhao H, Yuan J, et al. Perineural invasion as an independent predictor of biochemical recurrence in prostate cancer following radical prostatectomy or radiotherapy:a systematic review and meta-analysis. BMC Urol. 2018;18:5.","journal-title":"BMC Urol."},{"key":"20016_CR117","doi-asserted-by":"publisher","DOI":"10.4274\/uob.galenos.2023.2023.3.1","author":"\u015e Kumsar","year":"2024","unstructured":"Kumsar \u015e, Aslan G, S\u00fcer E, Akdo\u011fan B, S\u00f6zen S, G\u00fcl\u015fen M, et al. The effect of perineural invasion on biochemical recurrence-free survival following nerve-sparing radical prostatectomy. Bull Urooncol. 2024. https:\/\/doi.org\/10.4274\/uob.galenos.2023.2023.3.1.","journal-title":"Bull Urooncol."},{"key":"20016_CR118","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/modpathol.2012.104","volume":"25","author":"A Chaux","year":"2012","unstructured":"Chaux A, Peskoe SB, Gonzalez-Roibon N, Schultz L, Albadine R, Hicks J, et al. Loss of PTEN expression is associated with increased risk of recurrence after prostatectomy for clinically localized prostate cancer. Mod Pathol. 2012;25:1543\u20139.","journal-title":"Mod Pathol."},{"key":"20016_CR119","doi-asserted-by":"publisher","first-page":"25","DOI":"10.56434\/j.arch.esp.urol.20257801.4","volume":"78","author":"W Zhu","year":"2025","unstructured":"Zhu W, Chen W. Examining the Association between ERG\/PTEN expression and biochemical recurrence in prostate cancer: a comprehensive meta-analysis. Arch Espa\u00f1oles Urol. 2025;78:25.","journal-title":"Arch Espa\u00f1oles Urol."},{"key":"20016_CR120","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1158\/1078-0432.CCR-09-2871","volume":"16","author":"DJ Gallagher","year":"2010","unstructured":"Gallagher DJ, Gaudet MM, Pal P, Kirchhoff T, Balistreri L, Vora K, et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010;16:2115\u201321.","journal-title":"Clin Cancer Res."},{"key":"20016_CR121","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s12894-025-01840-5","volume":"25","author":"CE Yoon","year":"2025","unstructured":"Yoon CE, Kang S, Rhew SA, Kwon HJ, Shin D, Moon HW, et al. Genetic alterations of prostate cancer: in localized and metastatic prostate cancer. BMC Urol. 2025;25:166.","journal-title":"BMC Urol."},{"key":"20016_CR122","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2025.5521","volume":"55","author":"Y Ko","year":"2025","unstructured":"Ko Y, Won J, Jin H, Nguyen N, Won Y, Nsanzimana V, et al. ABCG8-mediated sterol efflux increases cancer cell progression via the LRP6\/Wnt\/\u03b2-catenin signaling pathway in radiotherapy-resistant MDA-MB-231 triple-negative breast cancer cells. Int J Mol Med. 2025;55:1\u201316.","journal-title":"Int J Mol Med."},{"key":"20016_CR123","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.3390\/ijms25105254","volume":"25","author":"SM M\u00fcller","year":"2024","unstructured":"M\u00fcller SM, J\u00fccker M. The functional roles of the Src homology 2 domain-containing inositol 5-Phosphatases SHIP1 and SHIP2 in the pathogenesis of human diseases. IJMS. 2024;25:5254.","journal-title":"IJMS."},{"key":"20016_CR124","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.18632\/aging.205440","volume":"16","author":"L Lu","year":"2024","unstructured":"Lu L, Lei Y, Li Y, Wang L. LRP6 is a potential biomarker of kidney clear cell carcinoma related to prognosis and immune infiltration. Aging. 2024;16:1484\u201395.","journal-title":"Aging."},{"key":"20016_CR125","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10717","volume":"7","author":"MP Whyte","year":"2023","unstructured":"Whyte MP, Mumm S, Baker JC, Zhang F, Sedighi H, Duan S, et al. LRP6 high bone mass characterized in two generations harboring a unique mutation of low-density lipoprotein receptor-related Protein 6. JBMR Plus. 2023;7:e10717.","journal-title":"JBMR Plus."},{"key":"20016_CR126","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s11658-023-00420-5","volume":"28","author":"J Wang","year":"2023","unstructured":"Wang J, Yang H, Ma X, Liu J, Li L, Chen L, et al. LRP6\/filamentous-actin signaling facilitates osteogenic commitment in mechanically induced periodontal ligament stem cells. Cell Mol Biol Lett. 2023;28:7.","journal-title":"Cell Mol Biol Lett."},{"key":"20016_CR127","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22:138.","journal-title":"Mol Cancer."},{"key":"20016_CR128","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.907625","volume":"12","author":"S Wang","year":"2022","unstructured":"Wang S, Yang X, Yu Z, Du P, Sheng X, Cao Y, et al. The values of systemic immune-inflammation index and neutrophil\u2013lymphocyte ratio in predicting biochemical recurrence in patients with localized prostate cancer after radical prostatectomy. Front Oncol. 2022;12:907625.","journal-title":"Front Oncol."},{"key":"20016_CR129","doi-asserted-by":"publisher","first-page":"1372837","DOI":"10.3389\/fimmu.2024.1372837","volume":"15","author":"OE Molina","year":"2024","unstructured":"Molina OE, LaRue H, Simonyan D, Hovington H, Vittrant B, T\u00eatu B, et al. Regulatory and memory T lymphocytes infiltrating prostate tumors predict long term clinical outcomes. Front Immunol. 2024;15:1372837.","journal-title":"Front Immunol."},{"key":"20016_CR130","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3892\/ol.2022.13625","volume":"25","author":"Y-P Sun","year":"2022","unstructured":"Sun Y-P, Ke Y-L, Li X. Prognostic value of CD8+ tumor-infiltrating T cells in patients with breast cancer: a systematic review and meta-analysis. Oncol Lett. 2022;25:39.","journal-title":"Oncol Lett."},{"key":"20016_CR131","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1073\/pnas.0611618104","volume":"104","author":"P Sharma","year":"2007","unstructured":"Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA. 2007;104:3967\u201372.","journal-title":"Proc Natl Acad Sci USA."},{"key":"20016_CR132","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/pros.24068","volume":"81","author":"Y Yang","year":"2021","unstructured":"Yang Y, Attwood K, Bshara W, Mohler JL, Guru K, Xu B, et al. High intratumoral CD8+ T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy. Prostate. 2021;81:20\u20138.","journal-title":"Prostate."},{"key":"20016_CR133","doi-asserted-by":"publisher","first-page":"1401097","DOI":"10.3389\/fimmu.2024.1401097","volume":"15","author":"M Zvirble","year":"2024","unstructured":"Zvirble M, Survila Z, Bosas P, Dobrovolskiene N, Mlynska A, Zaleskis G, et al. Prognostic significance of soluble PD-L1 in prostate cancer. Front Immunol. 2024;15:1401097.","journal-title":"Front Immunol."},{"key":"20016_CR134","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35612","volume":"131","author":"AH Bryce","year":"2025","unstructured":"Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, et al. Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: consensus recommendations from the US Prostate Cancer Conference 2024. Cancer. 2025;131:e35612.","journal-title":"Cancer."},{"key":"20016_CR135","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41391-023-00712-z","volume":"27","author":"ND Shore","year":"2024","unstructured":"Shore ND, Moul JW, Pienta KJ, Czernin J, King MT, Freedland SJ. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification. Prostate Cancer Prostatic Dis. 2024;27:192\u2013201.","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"20016_CR136","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/therapeutics2040016","volume":"2","author":"P Simon-Silva","year":"2025","unstructured":"Simon-Silva P, Del Castillo-Acu\u00f1a R, Saavedra-Bejarano J, Sanchez-Galvez A, Lazo-Prados A, Blanco-Villar ML. Androgen deprivation therapy and salvage radiotherapy in post-radical prostatectomy biochemical recurrence of prostate cancer: current evidence. Therapeutics. 2025;2:16.","journal-title":"Therapeutics."},{"key":"20016_CR137","doi-asserted-by":"publisher","first-page":"8149","DOI":"10.3390\/curroncol30090591","volume":"30","author":"S Karim","year":"2023","unstructured":"Karim S, Lowther J, Gyulay G, O\u2019Sullivan D, Wallis CJD, Yip SM, et al. A real-world evidence study using Alberta-population-based data to describe treatment patterns for metastatic castration-sensitive prostate cancer patients (AWARENESS). Curr Oncol. 2023;30:8149\u201358.","journal-title":"Curr Oncol."},{"key":"20016_CR138","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.3390\/cancers13174257","volume":"13","author":"L Burgess","year":"2021","unstructured":"Burgess L, Roy S, Morgan S, Malone S. A review on the current treatment paradigm in high-risk prostate cancer. Cancers. 2021;13:4257.","journal-title":"Cancers"},{"key":"20016_CR139","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","volume":"20","author":"C Carrie","year":"2019","unstructured":"Carrie C, Magn\u00e9 N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange J-L, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20:1740\u20139.","journal-title":"Lancet Oncol."},{"key":"20016_CR140","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1470-2045(18)30757-5","volume":"20","author":"JW Denham","year":"2019","unstructured":"Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, et al. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR):10-year results from a randomised, phase 3, factorial trial. Lancet Oncol. 2019;20:267\u201381.","journal-title":"Lancet Oncol."},{"key":"20016_CR141","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.ijrobp.2025.07.1416","volume":"123","author":"HR Lukka","year":"2025","unstructured":"Lukka HR, Pugh SL, Shipley WU, Major PP, Sartor O, Dayes IS, et al. Long-term results of NRG\/RTOG 9601, a randomized trial of radiation with or without antiandrogens in patients receiving salvage prostate bed radiation therapy postprostatectomy. Int J Radiat Oncol Biol Phys. 2025;123:990\u20139.","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"20016_CR142","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","volume":"6","author":"RT Dess","year":"2020","unstructured":"Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, et al. Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer. JAMA Oncol. 2020;6:735\u201343.","journal-title":"JAMA Oncol."},{"key":"20016_CR143","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3390\/life13051072","volume":"13","author":"F Sugino","year":"2023","unstructured":"Sugino F, Nakane K, Kawase M, Ueda S, Tomioka M, Takeuchi Y, et al. Efficacy and safety of neoadjuvant luteinizing hormone-releasing hormone antagonist and tegafur-uracil chemohormonal therapy for high-risk prostate cancer. Life. 2023;13:1072.","journal-title":"Life."},{"key":"20016_CR144","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906370","volume":"12","author":"Q Ge","year":"2022","unstructured":"Ge Q, Xu H, Yue D, Fan Z, Chen Z, Xu J, et al. Neoadjuvant chemohormonal therapy in prostate cancer before radical prostatectomy: a systematic review and meta-analysis. Front Oncol. 2022;12:906370.","journal-title":"Front Oncol."},{"key":"20016_CR145","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/medsci9020024","volume":"9","author":"T Sasaki","year":"2021","unstructured":"Sasaki T, Nishikawa K, Kato M, Masui S, Yoshio Y, Sugimura Y, et al. Neoadjuvant chemohormonal therapy before radical prostatectomy for Japanese patients with high-risk localized prostate cancer. Med Sci. 2021;9:24.","journal-title":"Med Sci."},{"key":"20016_CR146","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/JCO.20.00315","volume":"38","author":"JA Eastham","year":"2020","unstructured":"Eastham JA, Heller G, Halabi S, Monk JP, Beltran H, Gleave M, et al. Cancer and leukemia group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer. J Clin Oncol. 2020;38:3042\u201350.","journal-title":"J Clin Oncol."},{"key":"20016_CR147","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3390\/diseases13040092","volume":"13","author":"M Kawase","year":"2025","unstructured":"Kawase M, Washino S, Nishino T, Yamasaki T, Fukushima H, Iwatani K, et al. Neoadjuvant chemohormonal therapy versus pelvic lymphadenectomy on biochemical recurrence in patients with high- or very-high-risk prostate cancer undergoing robot-assisted radical prostatectomy. Diseases. 2025;13:92.","journal-title":"Diseases."},{"issue":"199","key":"20016_CR148","first-page":"1","volume":"2023","author":"DEGRO","year":"2023","unstructured":"DEGRO. Abstractbuch. Strahlenther Onkol. 2023;2023(199):1\u2013192.","journal-title":"Strahlenther Onkol."},{"key":"20016_CR149","volume":"49","author":"N Andratschke","year":"2024","unstructured":"Andratschke N, Willmann J, Appelt AL, Day M, Kronborg C, Massaccesi M, et al. Reirradiation: Still navigating uncharted waters? Clin Transl Radiat Oncol. 2024;49:100871.","journal-title":"Clin Transl Radiat Oncol."},{"key":"20016_CR150","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","volume":"399","author":"A Pollack","year":"2022","unstructured":"Pollack A, Karrison TG, Balogh AG, Gomella LG, Low DA, Bruner DW, et al. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet. 2022;399:1886\u2013901.","journal-title":"Lancet."},{"key":"20016_CR151","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","volume":"80","author":"P Ghadjar","year":"2021","unstructured":"Ghadjar P, Hayoz S, Bernhard J, Zwahlen DR, H\u00f6lscher T, Gut P, et al. Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09\/10 randomized phase 3 trial. Eur Urol. 2021;80:306\u201315.","journal-title":"Eur Urol."},{"key":"20016_CR152","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1001\/jamaoncol.2023.7291","volume":"10","author":"MK Buyyounouski","year":"2024","unstructured":"Buyyounouski MK, Pugh SL, Chen RC, Mann MJ, Kudchadker RJ, Konski AA, et al. Noninferiority of hypofractionated vs conventional postprostatectomy radiotherapy for genitourinary and gastrointestinal symptoms: the NRG-GU003 phase 3 randomized clinical trial. JAMA Oncol. 2024;10:584\u201391.","journal-title":"JAMA Oncol."},{"key":"20016_CR153","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","volume":"397","author":"AB Jani","year":"2021","unstructured":"Jani AB, Schreibmann E, Goyal S, Halkar R, Hershatter B, Rossi PJ, et al. EMPIRE-1: randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET\/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer. Lancet. 2021;397:1895\u2013904.","journal-title":"Lancet."},{"key":"20016_CR154","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.3746","author":"C Belliveau","year":"2025","unstructured":"Belliveau C, Saad F, Duplan D, Petit C, Delouya G, Taussky D, et al. Prostate-specific membrane antigen PET-guided intensification of salvage radiotherapy after radical prostatectomy: a phase 2 randomized clinical trial. JAMA Oncol. 2025. https:\/\/doi.org\/10.1001\/jamaoncol.2025.3746.","journal-title":"JAMA Oncol."},{"key":"20016_CR155","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.eururo.2025.03.009","volume":"88","author":"M Covas Moschovas","year":"2025","unstructured":"Covas Moschovas M, Saikali S, Sandri M, Bravi C, Falagario U, Nathan A, et al. Outcomes of salvage robotic-assisted radical prostatectomy: high-volume multicentric data from the European Association of Urology Robotic Urology Section Scientific Working Group. Eur Urol. 2025;88:103\u201313.","journal-title":"Eur Urol."},{"key":"20016_CR156","doi-asserted-by":"publisher","first-page":"1534739","DOI":"10.3389\/fonc.2025.1534739","volume":"15","author":"S Zhu","year":"2025","unstructured":"Zhu S, Liu J, Shen B, Xu H, Zhong W, Jin S. Oncological effects and complications of salvage cryotherapy for radio-recurrent prostate cancer: a systematic review and meta-analysis. Front Oncol. 2025;15:1534739. https:\/\/doi.org\/10.3389\/fonc.2025.1534739.","journal-title":"Front Oncol."},{"issue":"7","key":"20016_CR157","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.3390\/curroncol31070270","volume":"31","author":"S Sobhani","year":"2024","unstructured":"Sobhani S, Dadabhoy A, Ghoreifi A, Lebastchi AH. Salvage high-intensity focused ultrasound for prostate cancer after radiation failure: a narrative review. Curr Oncol. 2024;31(7):3669\u201381. https:\/\/doi.org\/10.3390\/curroncol31070270.","journal-title":"Curr Oncol."},{"key":"20016_CR158","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/s00345-023-04534-5","volume":"41","author":"F Falkenbach","year":"2023","unstructured":"Falkenbach F, Knipper S, Koehler D, Ambrosini F, Steuber T, Graefen M, et al. Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support. World J Urol. 2023;41:2343\u201350.","journal-title":"World J Urol."},{"key":"20016_CR159","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/JU.0000000000003494","volume":"210","author":"M Perera","year":"2023","unstructured":"Perera M, Touijer KA. Point-counterpoint: radioisotope-guided lymphadenectomy for pelvic node staging: the SENTINELLE study. J Urol. 2023;210:244\u20136.","journal-title":"J Urol."},{"key":"20016_CR160","doi-asserted-by":"publisher","first-page":"12095","DOI":"10.3390\/ijms222212095","volume":"22","author":"KA Plichta","year":"2021","unstructured":"Plichta KA, Graves SA, Buatti JM. Prostate-specific membrane antigen (PSMA) theranostics for treatment of oligometastatic prostate cancer. IJMS. 2021;22:12095.","journal-title":"IJMS."},{"key":"20016_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.722277","volume":"11","author":"TSC Ng","year":"2021","unstructured":"Ng TSC, Gao X, Salari K, Zlatev DV, Heidari P, Kamran SC. Incorporating PSMA-targeting theranostics into personalized prostate cancer treatment: a multidisciplinary perspective. Front Oncol. 2021;11:722277.","journal-title":"Front Oncol."},{"key":"20016_CR162","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.929444","volume":"12","author":"M Alberto","year":"2022","unstructured":"Alberto M, Yim A, Papa N, Siva S, Ischia J, Touijer K, et al. Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer. Front Oncol. 2022;12:929444.","journal-title":"Front Oncol."},{"key":"20016_CR163","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00345-025-05950-5","volume":"43","author":"SM Vorbach","year":"2025","unstructured":"Vorbach SM, Rittmayer H, Seppi T, Nilica B, Kafka M, Ganswindt U. PSMA-PET\/CT-based salvage elective nodal radiotherapy for lymph node recurrence following radical prostatectomy. World J Urol. 2025;43:571.","journal-title":"World J Urol."},{"key":"20016_CR164","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s00345-024-05189-6","volume":"42","author":"R Mayr","year":"2024","unstructured":"Mayr R, Engelmann SU, Yang Y, Haas M, Schmid T, Schnabel MJ, et al. Prostate-specific membrane antigen-radioguided surgery salvage lymph node dissection: experience with fifty oligorecurrent prostate cancer patients. World J Urol. 2024;42:483.","journal-title":"World J Urol."},{"key":"20016_CR165","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6:650.","journal-title":"JAMA Oncol."},{"key":"20016_CR166","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.3390\/cancers15153751","volume":"15","author":"L Evangelista","year":"2023","unstructured":"Evangelista L, Fanti S. PET\/CT in prostate cancer. Cancers. 2023;15:3751.","journal-title":"Cancers."},{"key":"20016_CR167","doi-asserted-by":"publisher","first-page":"16","DOI":"10.3390\/diagnostics8010016","volume":"8","author":"N Lenzo","year":"2018","unstructured":"Lenzo N, Meyrick D, Turner J. Review of gallium-68 PSMA PET\/CT imaging in the management of prostate cancer. Diagnostics. 2018;8:16.","journal-title":"Diagnostics."},{"key":"20016_CR168","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40644-016-0072-6","volume":"16","author":"I Rauscher","year":"2016","unstructured":"Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M. 68Ga-PSMA ligand PET\/CT in patients with prostate cancer: how we review and report. Cancer Imaging. 2016;16:14.","journal-title":"Cancer Imaging."},{"key":"20016_CR169","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40644-023-00599-y","volume":"23","author":"W Yu","year":"2023","unstructured":"Yu W, Zhao M, Deng Y, Liu S, Du G, Yan B, et al. Meta-analysis of 18 F-PSMA-1007 PET\/CT, 18 F-FDG PET\/CT, and 68Ga-PSMA PET\/CT in diagnostic efficacy of prostate Cancer. Cancer Imaging. 2023;23:77.","journal-title":"Cancer Imaging."},{"key":"20016_CR170","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1053\/j.semnuclmed.2022.04.004","volume":"52","author":"R Manafi-Farid","year":"2022","unstructured":"Manafi-Farid R, Askari E, Shiri I, Pirich C, Asadi M, Khateri M, et al. [18F]FDG-PET\/CT radiomics and artificial intelligence in lung cancer: technical aspects and potential clinical applications. Sem Nucl Med. 2022;52:759\u201380.","journal-title":"Sem Nucl Med."},{"key":"20016_CR171","doi-asserted-by":"publisher","DOI":"10.2196\/60323","volume":"10","author":"A Janbain","year":"2024","unstructured":"Janbain A, Farolfi A, Guenegou-Arnoux A, Romengas L, Scharl S, Fanti S, et al. A Machine learning approach for predicting biochemical outcome after PSMA-PET\u2013guided salvage radiotherapy in recurrent prostate cancer after radical prostatectomy: retrospective study. JMIR Cancer. 2024;10:e60323.","journal-title":"JMIR Cancer."},{"key":"20016_CR172","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1007\/s00259-024-06734-6","volume":"51","author":"T Li","year":"2024","unstructured":"Li T, Xu M, Yang S, Wang G, Liu Y, Liu K, et al. Development and validation of [18 F]-PSMA-1007 PET-based radiomics model to predict biochemical recurrence-free survival following radical prostatectomy. Eur J Nucl Med Mol Imaging. 2024;51:2806\u201318.","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"20016_CR173","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12885-025-13628-9","volume":"25","author":"L Cao","year":"2025","unstructured":"Cao L, He R, Zhang A, Li L, Cao W, Liu N, et al. Development of a deep learning system for predicting biochemical recurrence in prostate cancer. BMC Cancer. 2025;25:232.","journal-title":"BMC Cancer."},{"key":"20016_CR174","doi-asserted-by":"publisher","first-page":"7079","DOI":"10.3390\/jcm14197079","volume":"14","author":"T Zhang","year":"2025","unstructured":"Zhang T, Ide H, Lu J, Lu Y, China T, Nagata M, et al. Predicting biochemical recurrence after robot-assisted prostatectomy with interpretable machine learning model. JCM. 2025;14:7079.","journal-title":"JCM."},{"key":"20016_CR175","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.12.007","author":"TM Morgan","year":"2025","unstructured":"Morgan TM, Ren Y, Tang S, Zwerink W, Chen E, Mitani A, et al. Development and validation of a multimodal artificial intelligence\u2013derived digital pathology\u2013based biomarker predicting metastasis among patients with biochemical recurrence after radical prostatectomy in NRG\/RTOG Trials. Eur Urol. 2025. https:\/\/doi.org\/10.1016\/j.eururo.2025.12.007.","journal-title":"Eur Urol."},{"key":"20016_CR176","doi-asserted-by":"crossref","unstructured":"Abstracts. BJU Int. 2024;133:4\u201398.","DOI":"10.1111\/bju.16252"},{"key":"20016_CR177","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.3390\/cancers16213596","volume":"16","author":"J Liu","year":"2024","unstructured":"Liu J, Zhang H, Woon DTS, Perera M, Lawrentschuk N. Predicting biochemical recurrence of prostate cancer post-prostatectomy using artificial intelligence: a systematic review. Cancers. 2024;16:3596.","journal-title":"Cancers."},{"key":"20016_CR178","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1007\/s00261-025-04892-1","volume":"50","author":"M Salimi","year":"2025","unstructured":"Salimi M, Vadipour P, Houshi S, Yazdanpanah F, Seifi S. MRI-based radiomics for prediction of biochemical recurrence in prostate cancer: a systematic review and meta-analysis. Abdom Radiol. 2025;50:4748\u201371.","journal-title":"Abdom Radiol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20016-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20016-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20016-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:02:06Z","timestamp":1789671726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20016-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":178,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["20016"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20016-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}}]}}